Medical Technologies

Pogge and Hollis on the Trade-off between access and incentives

This is a comment on the references to compulsory licensing in the Hollis/Pogge HIF book that are quoted below.

http://www.keionline.org/blogs/2008/11/18/excerpts-from-hif-compulsory-licensing/
Aidan Hollis and Thomas Pogge, The Health Impact Fund, Making New Medicines Accessible for All, A Report of Incentives for Global Health, 2008.

Why the HIF rejected open licensing

In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:

From Bamako: WHO strategy on research for health

The Global Ministerial Forum on Research for Health is meeting in Bamako, Mali from November 17-19, 2008. This Ministerial is organized by the Council on Health Research for Development (COHRED), Global Forum for Health Research, the Republic of Mali, the United Nations Cultural, Scientific and Educational Organization (UNESCO), the World Bank and the World Health Organization (WHO), and coordinated by the Bamako 2008 Secretariat.

Excerpts from HIF: compulsory licensing

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.

Page 53-54

HIF on the Sanders prize fund bill

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.

Page 105-106

Medical Innovation Prize Act of 2007

The Medical Innovation Prize Fund (S.2210, 110th Congress) and the WTO TRIPS Agreement

I have been asked to elaborate on the relationship between the Medical Innovation Prize Fund (S.2210, 110th Congress) and the WTO TRIPS Agreement.

For centuries, innovation inducement prizes have been suggested as a mechanism to stimulate investments in a wide range of topics. (See, for example, Selected Innovation Prizes and Reward Programs, KEI Research Note 2008:1). During most of this period, the patent system has also existed.

Require or Encourage? IGWG text on open access

Re: The WHO IGWG Text on Access to Publicly Funded Research Provision, from “Requirement” to “Encouragement”?

One of the outcomes of the Nov. 5-10, 2007 second session of the WHO Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG2) is a provision on access to government funded research.

Mexico’s proposed deletion of consumer rights in the IGWG Text

Tomorrow morning (Friday the 9th), the IGWG finally takes up Element 5, the intellectual property text. These are the deletions to the text being requested by Mexico.

———-
ELEMENT 3

This would include:
building innovative capacity in science and technology and traditional medicine/genetic resources, in agreement with the legislation existing in the Parties on this issues;
rational health-orientated intellectual property management. (Mexico suggest delete)

Propuesta: Pools de Patentes para el Cancer

Boletín Fármacos has asked me to write a short summary of one of KEI’s projects. I chose to present a patent pool for medical technologies related to the prevention and treatment of cancer. Please find the article below. It is also available: http://www.boletinfarmacos.org/092007/ventana_abierta.asp

Syndicate content